Shanghai Hile Bio-tech

603718 · SHG · Healthcare / Biotechnology

2.95CNY-0.03 (-1.01%)

Price History

Full chart

Market Stats

Previous Close2.98

Open2.99

Day Range2.94 – 2.99

52-Week Range2.57 – 7.38

Volume3.54M

Market Cap2.01B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.49

Dividend Yield0.00%

Beta0.21

50-Day Avg3.00

200-Day Avg4.11

About

Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent assay reagents, and related diagnostic kits, including immunoglobulin G subtype 4, helicobacter pylori, adiponectin, creatine kinase isoenzyme, hepatobiliary acid, cardiac troponin I, heparin binding protein, N-acetyl-O-D-glucosidase, muscle soda, salivary glycan antigen KL-6 kits. It also provides oral bone repair materials, implants, natural bone repair materials, dental restorative materials, collagen-based bone repair matrix, and soft tissue repair matrix. The company was founded in 1981 and is based in Shanghai, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Benyi Han
Employees340
HeadquartersNo. 138 Huaihai Middle Road, Shanghai, China, 200001, China
Websitehttps://www.hile-bio.com

Leadership

Mr. Benyi HanGM & Director · b. 1965
Mr. Wang XingchunFinancial Officer · b. 1970
Mr. Xiao ChenDeputy GM & Director · b. 1985
Ms. Dongchan PuDeputy GM & Secretary of the Board · b. 1982
Mr. Xiang XiaoqiangDeputy General Manager · b. 1979
Jun Qin HuangAccounting Supervisor

Financials

Income Statement

Currency: CNY	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	260.13M	310.84M	318.79M	285.27M	316.58M	343.34M	303.65M	254.57M	277.99M	259.13M	347.29M	299.99M	240.72M	271.04M	187.87M
Growth (%)	-	+19.50%	+2.56%	-10.51%	+10.97%	+8.45%	-11.56%	-16.16%	+9.20%	-6.79%	+34.02%	-13.62%	-19.76%	+12.59%	-30.69%
Cost of Revenue	61.51M	69.07M	71.07M	61.80M	73.53M	84.03M	69.22M	112.92M	150.48M	140.20M	158.40M	124.61M	120.30M	110.39M	52.28M
Gross Profit	198.61M	241.77M	247.72M	223.47M	243.05M	259.31M	234.43M	141.65M	127.51M	118.93M	188.89M	175.38M	120.42M	160.65M	135.59M
Gross Margin	76.35%	77.78%	77.71%	78.34%	76.77%	75.53%	77.20%	55.64%	45.87%	45.90%	54.39%	58.46%	50.02%	59.27%	72.17%
Operating Expense	81.89M	117.58M	115.53M	118.74M	133.43M	186.59M	129.59M	119.47M	120.49M	140.54M	131.65M	105.46M	65.25M	-13.88M	88.51M
Operating Income	116.73M	124.20M	132.19M	104.73M	109.61M	72.72M	104.84M	22.18M	7.02M	-21.61M	57.24M	69.92M	55.17M	174.53M	47.07M
Operating Margin	44.87%	39.95%	41.47%	36.71%	34.62%	21.18%	34.53%	8.71%	2.53%	-8.34%	16.48%	23.31%	22.92%	64.39%	25.06%
EBITDA	123.22M	154.21M	164.63M	151.35M	138.26M	128.43M	170.93M	67.46M	82.66M	52.56M	126.56M	182.70M	97.07M	248.35M	-165.67M
EBITDA Margin	47.37%	49.61%	51.64%	53.05%	43.67%	37.41%	56.29%	26.50%	29.74%	20.28%	36.44%	60.90%	40.32%	91.63%	-88.19%
Net Income	107.27M	112.55M	118.79M	101.22M	95.40M	85.54M	113.74M	21.30M	12.15M	8.93M	53.86M	121.61M	62.87M	171.18M	-311.44M
Net Income Margin	41.24%	36.21%	37.26%	35.48%	30.14%	24.91%	37.46%	8.37%	4.37%	3.44%	15.51%	40.54%	26.12%	63.16%	-165.77%
R&D	-	14.33M	14.93M	17.86M	19.68M	25.13M	20.16M	27.28M	29.64M	29.53M	28.64M	29.94M	24.97M	32.79M	22.67M
R&D as % of Total Revenue	-	4.61%	4.68%	6.26%	6.22%	7.32%	6.64%	10.72%	10.66%	11.39%	8.25%	9.98%	10.37%	12.10%	12.07%
Interest Expense	-	460.83K	663.33K	6.14M	152.26K	6.00M	11.80M	14.90M	18.17M	17.69M	12.53M	10.31M	5.39M	5.49M	1.26M
Interest Expense % of Total Revenue	-	0.15%	0.21%	2.15%	0.05%	1.75%	3.89%	5.85%	6.54%	6.83%	3.61%	3.44%	2.24%	2.03%	0.67%

Balance Sheet

Currency: CNY	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	504.03M	560.66M	600.84M	654.48M	1.24B	1.48B	1.60B	1.75B	1.70B	1.79B	1.84B	1.51B	1.66B	1.83B	1.13B
Total Liabilities	98.29M	92.78M	100.17M	95.98M	277.01M	474.55M	526.83M	722.81M	708.72M	824.54M	856.90M	403.25M	482.96M	123.65M	229.14M
Total Equity	405.74M	467.89M	487.98M	547.20M	924.04M	981.58M	1.07B	1.06B	1.06B	1.06B	1.01B	1.14B	1.22B	1.56B	882.04M
Cash	202.38M	258.44M	274.07M	266.72M	402.25M	284.33M	96.28M	47.14M	51.25M	18.01M	153.04M	156.55M	140.74M	358.50M	214.31M
Total Debt	-	20.00M	-	-	86.40M	210.84M	179.95M	50.00M	427.71M	466.91M	14.63M	41.21M	50.83M	49.35M	-
Net Debt	-202.38M	-238.44M	-274.07M	-266.72M	-315.85M	-73.48M	83.68M	2.86M	376.46M	448.91M	-138.41M	-115.34M	-89.91M	-309.16M	-

Cash Flow

Currency: CNY	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	149.61M	122.48M	147.63M	110.22M	201.69M	108.39M	34.92M	18.92M	59.25M	167.68M	43.63M	292.91M	-2.94M	46.47M	58.83M
Investing Cash Flow	68.66M	-34.51M	-24.84M	-73.12M	-437.46M	-315.22M	-276.41M	-104.31M	-68.95M	-225.84M	41.54M	66.13M	-171.09M	38.34M	-
Financing Cash Flow	-106.04M	-54.05M	-85.16M	-44.45M	371.31M	88.83M	53.47M	36.15M	13.66M	25.04M	50.01M	-355.53M	159.99M	126.29M	-
Capital Expenditure	51.64M	34.58M	24.86M	87.07M	139.18M	136.16M	86.04M	112.29M	39.03M	34.12M	37.78M	19.85M	7.81M	8.39M	12.17M
Free Cash Flow	97.97M	87.89M	122.77M	23.15M	62.51M	-27.77M	-51.12M	-93.37M	20.22M	133.56M	5.85M	273.06M	-16.18M	38.08M	46.66M
Dividends Paid	106.04M	50.86M	99.36M	42.00M	137.53M	35.61M	35.64M	39.79M	6.44M	3.86M	2.70M	683.94K	36.51M	21.57M	122.26M
FCF to OCF	65.49%	71.76%	83.16%	21.00%	30.99%	-25.62%	-146.39%	-493.59%	34.13%	79.65%	13.42%	93.22%	550.67%	81.95%	79.31%
Dividend Paid to FCF	108.24%	57.87%	80.93%	181.43%	220.03%	-128.23%	-69.72%	-42.61%	31.84%	2.89%	46.20%	0.25%	-225.68%	56.65%	262.01%

Earnings

Report Date	Oct 22, 2015	Mar 15, 2016	Apr 26, 2016	Jul 20, 2016	Oct 26, 2016	Apr 19, 2017	Aug 25, 2017	Oct 28, 2017	Apr 26, 2018	Aug 30, 2018	Oct 29, 2018	Apr 26, 2019	Aug 30, 2019	Oct 31, 2019	Apr 29, 2020	Aug 31, 2020	Oct 28, 2020	Apr 24, 2021	Sep 2, 2021	Oct 29, 2021	Apr 29, 2022	Aug 30, 2022	Oct 29, 2022	Apr 29, 2023
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.03	0.03	0.04	0.04	0.03	0.04	0.04	0.05	0.05	0.02	0.02	-0.04	0.01	0.01	0.01	-0.01	0.01	0.02	0.02	0.02	0.03	0.03	0.02	0.02
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	-	-	-	-	-	-	-	-	Pre-market	-	-	-

Key Statistics & Ratios

Market Cap2.01B

Enterprise Value1.75B

Trailing P/E0.00

Forward P/E0.00

Price / Sales9.37

Price / Book2.23

EPS-0.49

Book Value1.34

Revenue (TTM)213.98M

Gross Profit (TTM)135.12M

EBITDA49.74M

Profit Margin-148.71%

Operating Margin11.81%

Return on Equity-22.58%

Return on Assets1.29%

Shares Outstanding648.98M

Shares Float347.84M

Beta0.21

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio30.11%

Dividends

20231×

0.06Jul 13, 2023

20211×

0.00Jul 1, 2021

20201×

0.01Jul 15, 2020

20191×

0.01Jul 18, 2019

20181×

0.06Jul 26, 2018

20171×

0.04Jul 7, 2017

20161×

0.10May 5, 2016

Stock Splits

May 5, 201623:10